Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14834015 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL19895215 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2863609 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL21122061 | 0.95 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL8020222 | 0.95 | LPAR1 (0.54) | LPAR1LPAR3TRPV1 | |
| SCHEMBL22401449 | 0.95 | LPAR1 (0.54) | LPAR1LPAR3TRPV1 | |
| SCHEMBL8020229 | 0.95 | LPAR1 (0.54) | LPAR1LPAR3TRPV1 | |
| SCHEMBL25362066 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899325 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899581 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | claimed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | claimed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| EP-3521270-B1 | CATIONIC LIPID COMPOUND | KYOWA KIRIN CO LTD (JP) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521270-A1 | CATIONIC LIPID COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099738-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | ALDH1A1 1734/4885CNR1 3492/4885CNR2 3231/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | ALDH1A1 4724/4885CNR1 3144/4885CNR2 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.